Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$0.17 - $0.39 $1,757 - $4,031
10,336 New
10,336 $1,000
Q3 2022

Nov 14, 2022

BUY
$0.41 - $1.3 $5,803 - $18,402
14,156 New
14,156 $6,000
Q2 2020

Aug 17, 2020

SELL
$6.69 - $11.51 $113,776 - $195,750
-17,007 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$4.77 - $8.23 $81,123 - $139,967
17,007 New
17,007 $121,000

About NeuBase Therapeutics, Inc.


  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.